307. カナバン病 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 6 / 薬物数 : 8 - (DrugBank : 4) / 標的遺伝子数 : 2 - 標的パスウェイ数 : 2
薬物、開発者(Primary Sponsor)、臨床試験情報(症例登録開始年(Enrollment year)、フェーズ、ID、実施国)
AAV9 BBP-812
Aspa Therapeutics
2021 Phase 1/Phase 2 NCT04998396 United States
Glyceryl triacetate
Assistance Publique - Hôpitaux de Paris
2009 Phase 2 NCT00657748 France
GTA glyceryl triacetate
Shaare Zedek Medical Center
2008 - NCT00724802 Israel
GTA: glyceryltriacetate
Sheba Medical Center
2006 Phase 1 NCT00278707 Israel
Levetiracetam
Myrtelle Inc.
2021 Phase 1/Phase 2 NCT04833907 United States
Prednisone
Myrtelle Inc.
2021 Phase 1/Phase 2 NCT04833907 United States
RAAV-OLIG001-aspa
Myrtelle Inc.
2021 Phase 1/Phase 2 NCT04833907 United States
RAAV9-CB6-aspa
University of Florida
2022 - NCT05317780 United States
Aspa Therapeutics
2021 Phase 1/Phase 2 NCT04998396 United States
Glyceryl triacetate
Assistance Publique - Hôpitaux de Paris
2009 Phase 2 NCT00657748 France
GTA glyceryl triacetate
Shaare Zedek Medical Center
2008 - NCT00724802 Israel
GTA: glyceryltriacetate
Sheba Medical Center
2006 Phase 1 NCT00278707 Israel
Levetiracetam
Myrtelle Inc.
2021 Phase 1/Phase 2 NCT04833907 United States
Prednisone
Myrtelle Inc.
2021 Phase 1/Phase 2 NCT04833907 United States
RAAV-OLIG001-aspa
Myrtelle Inc.
2021 Phase 1/Phase 2 NCT04833907 United States
RAAV9-CB6-aspa
University of Florida
2022 - NCT05317780 United States